Consumers are being reminded to visit pharmacies for a bowel screening test
Clinical Genomics Technologies, an international healthcare company and manufacturer of the widely used BowelScreen Australia test kit, has reminded all Australians aged 50 years and over to complete a bowel cancer screening test every one to two years by visiting their GP or pharmacist during Bowel Cancer Awareness month.
Each year Bowel Cancer Australia dedicates the month of June to raising much needed awareness and funds for bowel cancer.
According to Mark Boyle, President, In Vitro Diagnostics at Clinical Genomics, the company’s support for Bowel Cancer Australia during the awareness month is underpinned by its commitment to the fact that bowel cancer screening saves lives.
“We are very proud of our contribution to bowel cancer screening in Australia. If you’ve bought a testing kit from an Australian pharmacy or used a kit from the annual Rotary programs, then chances are you’ve used a kit developed and distributed by Clinical Genomics. We are also very proud to partner with Bowel Cancer Australia during Bowel Cancer Awareness month to raise awareness of this important issue,” said Mr. Boyle.
Bowel cancer is Australia’s second largest cancer killer, taking more than 4,000 lives every year, despite it being one of the most treatable cancers if diagnosed early.
“It’s a very simple call to action,” said Mr Boyle. “All Australians aged over 50 should visit their GP, pharmacist or the Bowel Cancer Australia website to learn more about their screening options.”
Clinical Genomics developed and recently launched Colvera™ in the USA, a sensitive and specific blood-based circulating tumor DNA (ctDNA) test for colorectal cancer recurrence monitoring that detects gene changes in the blood.
Clinical Genomics anticipates that the test will be available in Australia in 2018.